Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single and multiple ascending dose trial of NTa53 in healthy Japanese adult male volunteers
jRCT2051210123Phase 1Completed
- Sponsor
- Nitto Medic
- Start
- Nov 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in allergic conjunctivitis (AC) (2 arms), sponsored by Nitto Medic. Primary endpoints: Pharmacokinetics of NTa53 and Safety and tolerability of NTa53. Started Nov 2021; status: completed.
02
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2051210123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210123.